DK2007885T3 - Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider - Google Patents

Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider

Info

Publication number
DK2007885T3
DK2007885T3 DK07723889.7T DK07723889T DK2007885T3 DK 2007885 T3 DK2007885 T3 DK 2007885T3 DK 07723889 T DK07723889 T DK 07723889T DK 2007885 T3 DK2007885 T3 DK 2007885T3
Authority
DK
Denmark
Prior art keywords
therapeutic polypeptides
enhancing
vivo recovery
polypeptides
recovery
Prior art date
Application number
DK07723889.7T
Other languages
English (en)
Inventor
Thomas Weimer
Hubert Metzner
Stefan Schulte
Wiegand Lang
Wilfried Wormsbaecher
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2007885T3 publication Critical patent/DK2007885T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK07723889.7T 2006-04-11 2007-04-02 Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider DK2007885T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007552 2006-04-11
PCT/EP2007/002948 WO2007115724A2 (en) 2006-04-11 2007-04-02 Method of increasing the in vivo recovery of therapeutic polypeptides

Publications (1)

Publication Number Publication Date
DK2007885T3 true DK2007885T3 (da) 2010-11-08

Family

ID=36778259

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07723889.7T DK2007885T3 (da) 2006-04-11 2007-04-02 Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider

Country Status (12)

Country Link
US (3) US20100222554A1 (da)
EP (2) EP2007885B1 (da)
JP (1) JP2009533364A (da)
KR (1) KR101492422B1 (da)
AT (1) ATE474917T1 (da)
AU (1) AU2007236280B2 (da)
CA (1) CA2649199C (da)
DE (1) DE602007007923D1 (da)
DK (1) DK2007885T3 (da)
ES (1) ES2349024T3 (da)
PL (1) PL2007885T3 (da)
WO (1) WO2007115724A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US8754194B2 (en) * 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
AU2008311973B2 (en) * 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
SG10201913700SA (en) * 2010-07-09 2020-03-30 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
EP3461905B1 (en) * 2010-11-22 2020-08-05 Amicus Therapeutics, Inc. Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
WO2020077114A2 (en) 2018-10-10 2020-04-16 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
WO2020084161A1 (en) * 2018-10-26 2020-04-30 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
EP0793504B1 (en) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 GPIb・脂質複合体およびその用途
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
JP4071105B2 (ja) * 2000-10-18 2008-04-02 マキシゲン・エイピーエス プロテインcまたは活性化プロテインc様分子
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1745141B2 (en) * 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
US8754194B2 (en) * 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Also Published As

Publication number Publication date
CA2649199C (en) 2015-01-20
US20100222554A1 (en) 2010-09-02
KR101492422B1 (ko) 2015-02-12
ES2349024T3 (es) 2010-12-21
WO2007115724A2 (en) 2007-10-18
CA2649199A1 (en) 2007-10-18
EP2007885A2 (en) 2008-12-31
ATE474917T1 (de) 2010-08-15
PL2007885T3 (pl) 2010-12-31
DE602007007923D1 (de) 2010-09-02
EP2263696A1 (en) 2010-12-22
JP2009533364A (ja) 2009-09-17
KR20090008329A (ko) 2009-01-21
AU2007236280B2 (en) 2013-07-25
US20140248686A1 (en) 2014-09-04
WO2007115724A3 (en) 2008-03-20
AU2007236280A1 (en) 2007-10-18
EP2007885B1 (en) 2010-07-21
US20130337532A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
AR062030A1 (es) Proteinas de fusion de exendina
JOP20190083A1 (ar) بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
DK3050963T3 (da) Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
NZ703581A (en) Anti-cd70 antibody drug conjugates
DK2035447T3 (da) Polypeptid
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
SG162687A1 (en) Caustic stable chromatography ligands
BRPI0817294A2 (pt) Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
BRPI0716744A2 (pt) proteínas de fusão de albumina
MX2012003939A (es) Fusiones y conjugados de farmaco.
BRPI0918947A2 (pt) proteína de fusão de anticorpo
EP2161287A4 (en) OPTIMIZED TACI FC FUSION PROTEINS
IL210175A0 (en) Fn14/trail fusion proteins
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
UY31123A1 (es) Proteinas de fusion natriureticas
WO2010014922A3 (en) Protein purification tags and uses thereof
ATE527345T1 (de) Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
WO2009131698A3 (en) PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
CY1116757T1 (el) Πεπτιδια που προσδενουν υποδοχεα αυξητικου παραγοντα 1 ομοιαζοντος με ινσουλινη
WO2008005470A3 (en) Polypeptides that bind membrane proteins